CA
PTCT icon

Clearstead Advisors’s PTC Therapeutics PTCT Stock Holding History

Clearstead Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7K Buy
+144
New +$10.4K ﹤0.01% 1934
2026
Q1 		– Sell
-51
Closed -$3.87K – 2717
2025
Q4 		$3.87K Sell
51
-72
-59% -$5.23K ﹤0.01% 2064
2025
Q3 		$7.55K Buy
123
+68
+124% +$3.54K ﹤0.01% 2011
2025
Q2 		$2.69K Buy
+55
New +$2.61K ﹤0.01% 2260

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Clearstead Advisors's PTCT Position: Q2 2026 in Review

Clearstead Advisors opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 144 shares worth $11.7K. The stake represents ﹤0.01% of the portfolio and ranks #1934 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in PTCT as recently as Q4 2025.

Clearstead Advisors first reported a position in PTCT in Q2 2025 and has held it in 4 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Clearstead Advisors held 144 shares of PTC Therapeutics worth $11.7K as of Q2 2026.
  • PTC Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1934 holding.
  • Clearstead Advisors first reported a position in PTC Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.